Tango Therapeutics principal accounting officer sells $198k in stock

On September 22, 2026, Jessica Newcomb, Principal Accounting Officer at Tango Therapeutics (NASDAQ: TNGX), sold 8,200 shares of the company's common stock. The transaction totaled $198,612 and occurred under a pre-established Rule 10b5-1 trading plan she adopted on June 23, 2026. Newcomb's stock sales were executed in three separate transactions, with shares changing hands at weighted average prices ranging from $22.80 to $25.17.

The company's shares have experienced significant growth, with a 178% increase year-to-date and 209% over the past year, currently trading at $24.63 per share. Despite this surge, InvestingPro's analysis suggests the stock is overvalued, categorizing TNGX among the most overvalued stocks it tracks. Following the sales, Newcomb retains ownership of 59,121 shares, comprising 43,666 unvested restricted stock units (RSUs) worth one share each.

These transactions come amid a series of developments for Tango Therapeutics, which reported a net loss of $0.37 per share for Q2 2026, surpassing H.C. Wainwright's estimate of $0.30 loss but falling short of analyst expectations. In response, H.C. Wainwright raised its price target to $68, maintaining a Buy rating. Guggenheim Securities also increased its price target to $35, citing the company's plans for a Phase 3 trial of vopimetostat in pancreatic ductal adenocarcinoma.

Mizuho Capital upgraded its price target to $40, applauding Tango's synergies in recent data for daraxonib combined with vopimetostat, while Stifel Nicolaus maintained a Buy rating with a $40 price target, anticipating positive updates on combination therapies at the ESMO 2026 conference. Finally, JPMorgan initiated coverage with an Overweight rating and $46 price target, highlighting Tango's progress in combination trials for pancreatic ductal adenocarcinoma and potentially non-small cell lung cancer.

Additionally, Tango Therapeutics appointed new executive leadership, with Fatma Ocak becoming chief commercial officer and Robert Azelby assuming the role of chairman of the board.